Shilpa Biologicals Pvt. Ltd. (SBPL) has announced the launch of PartnerPower™, a purpose-built digital transparency platform designed to give global sponsors uninterrupted, real-time insights into every stage of their biologics development and manufacturing programs.
Built as a unified digital data fabric, PartnerPower™ replaces traditional periodic reporting with a continuously live, collaborative environment that enables biopharmaceutical innovators worldwide to monitor the true state of their projects at any moment, from anywhere in the world. The platform delivers real-time visibility into process development laboratories and GMP manufacturing environments, giving sponsors direct access to operational data as it is generated. By linking information across R&D, analytical development, and manufacturing operations, it is designed to support tighter coordination, faster decision-making, and more efficient technology transfer.
The platform has also been developed with data integrity and sponsor confidentiality as core principles. Aligned with the expectations of global regulatory authorities, including the US FDA, EMA, and PMDA, it enables a continuous state of audit readiness.
Madhav Bhutada, Director, Shilpa Biologicals, said, “With PartnerPower™, we are setting a new global benchmark for what transparency in a CDMO partnership should look like. It allows our sponsors to innovate with complete confidence, knowing that every data point, every decision, and milestone is visible to them in real time.”
The launch of PartnerPower™ adds to Shilpa Biologicals’ continued investment in world-class biologics capabilities, including dedicated bioconjugation suites for Antibody-Drug Conjugates (ADCs), one of the world’s largest microbial sites, and a commercial mAbs facility. The team can be met at booth no 3351 at BIO San Diego’26.
